EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2021 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 24th day of March 2021, between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and Ellen M. Lintal of The Villages, Florida (the “Employee” or “Lintal “and amends and restates in its entirety any prior Employment Agreements between the parties.
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND MATERIAL TRANSFER AND RESEARCH AGREEMENTMaterial Transfer and Research Agreement • March 31st, 2021 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • Florida
This Agreement is made as of November 29, 2020 (“Effective Date”) by and between AIM IMMUNOTECH INC. (“AIM”), a corporation incorporated under the laws of Delaware, having an Offices at 2117 SW Hwy 484 Ocala Fl 34473 as the supplier of the experimental drug Ampligen® and Ronald Brus, individually and on behalf of Leyden Laboratories, B.V. (“Leyden Labs”) having an office at Keizersgracht 290A, 1016 EW Amsterdam, The Netherlands, (together referred to as “Companies”). AIM and Leyden Labs shall be referred to individually as a “Party” and together as the “Parties.”
FIRST AMENDMENT TO MANUFACTURE AND SUPPLY AGREEMENTManufacturing Agreement • March 31st, 2021 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
This First Amendment to the Manufacture and Supply Agreement (the “First Amendment”) is made effective as of December 23, 2020 (the “Effective Date”), by and between Pharmaceutics International, Inc. (“PII”) and AIM Immuno Tech Inc. (“Customer”).
